109: A pilot trial of unrelated donor umbilical cord blood transplanation (UCBT) augmented with cytokine-primed aldehyde dehydrogenase-bright (ALDHbr) cells  by Kurtzberg, J. et al.
produce adequate engraftment even when the CD34/kg content
is below what is considered a minimum target for PBSC alone.
Registry data may already exist to address this issue.
107
EVIDENCE OF SUCCESSFUL ALLOGENEIC TRANSPLANTAITON USING
CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FROM HEALTHY
DONORS
Kim, D.H.12, Jamal, N.1, Saragosa, R.1, Lipton, J.H.1, Gupta, V.1,
Kuruvilla, J.1, Messner, H.A.1 1Princess Margaret Hospital, Toronto,
ON, Canada; 2Samsung Medical Center, Seoul, Republic of Korea.
Between Sep 2003 and Dec 2005, the BMT program at Princess
Margaret Hospiral (Toronto, ON, Canada) performed 105 trans-
plants using cryopreserved PBSCs from allogeneic related donors.
The current study was aimed to evaluate the safety of cryopreser-
vation of PBSCs, to compare the clinical outcomes of cryopre-
served PBSCT with fresh PBSCT, and to evaluate the inﬂuence of
cryopreservation on colony forming unit (CFU) assay data of
PBSCs incluidng CFU-GM, BFU-E, CFU-MEG and CFU-
GEMM. As a control group, 106 patients receiving fresh PBSCTs
between Jun 2001 and Aug 2003 was compared.
All patients tolerated well to infusion without signiﬁcant toxicity.
The mean viability of thawed products was 71.21.0%. The me-
dian transplant dose of TNC and CD34 cells was 8.9108/Kg
and 5.0106/Kg, while that of CFU-GM, BFU-E, CFU-MEG
and CFU-GEMM was 118, 134, 19, 8.4104/Kg, respectively. No
differences in clinical outcomes were noted between cryo- vs.
fresh-PBSCT group: engraftment of neutrophil (p0.178) or
platelet (p0.785), acute GVHD (p0.113), chronic GVHD
(p0.673), recurrence (p0.295), non-relapse mortality
(p0.340), and overall survival (p0.668). The colony forming
activity was reduced by 24.62.5% for CFU-GM, 30.52.5% for
BFU-E, 61.43.1% for CFU-MEG, and 21.32.1% for CFU-
GEMM after cryopreservation. The transplant CD34 cell dose
correlates well with transplant dose of CFU-GM (p0.001),
BFU-E (p0.001), CFU-MEG (p0.001) and CFU-GEMM
(p0.049), but not with TNC dose. The group receiving higher
transplant CD34 cell dose showed signiﬁcantly faster engraft-
ment of neutrophil (0.5109/L, p0.012) and platelet
(20109/L, p0.013 and 100109/L, p0.009). Moreover,
transplant CFU-MEG dose showed good correlation with engraft-
ment of platelet above 20109/L (p0.029), 50109/L (p0.003),
and 100109/L (p0.001). In multivariate analysis, higher CFU-
MEG dose was strongly correlated with faster engraftment above
100109/L when taking into account as a continuous (p0.001) or
categorical variables (p0.040).
Conclusion
1) Cryopreserved PBSCT is safe in terms of infusion-related
toxocitiy, and showed equivalent transplant outcomes to fresh
PBSCT.
2) CFU-MEG decreases by 60% after cryopreservation, but
other CFUs showed similar decrease as viability.
3) Transplant CD34 cell dose correlated well with engraftment
of neutrophil and platelet. However, in terms of stable platelet
engraftment (100109/L), CFU-MEG dose seemed to be more
important factor than CD34 cell dose.
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DEVELOPMENT OF A MINIMALLY INVASIVE DEVICE AND METHOD FOR
RAPID, OUTPATIENT HARVEST OF BONE MARROW
Kraft, D.1, Milroy, C.1, MacKenzie, A.2, Ghazarossian, V.2 1Stanford
University School of Medicine, Stanford, CA; 2StemCor Systems Inc,
Menlo Park, CA.
Bone marrow is a rich source of adult stem cells. Traditional
methods for harvesting marrow derived stem cells are crude, te-
dious and expensive. We have developed a device and method for
the minimally invasive harvest of bone marrow which may enable
the rapid, convenient outpatient harvest of large quantities of
marrow derived cells under local anesthesia.
Marrow contains a rich supply of hematopoetic, mesenchymal
and other adult stem cell populations. Both marrow and mobilized
peripheral blood stem cells are currently utilized in BMT. For
allogeneic transplants, recent data suggests operatively harvested
marrow (as well as GCSF-primed marrow) may lead to less chronic
GVHD and better overall outcomes than mobilized PBSC grafts.
In addition to BMT, marrow derived cells may soon be utilized in
a variety of stem cell mediated regenerative therapies, resulting in
an increasing need for a simpliﬁed means for easy, rapid and
economical acquisition of bone marrow.
Current operative marrow harvests generally require 200 tro-
car insertions into the donor’s ileac crest, with each puncture/
aspirate enabling withdrawal of a only a small volume of marrow.
O.R. based harvests require general anesthesia, multiple staff, sup-
portive RBC transfusions, and often an overnight hospital stay.
Peripheral blood stem cell harvests, while less invasive, often re-
quire several rounds of expensive GCSF administration and multi-
hours apheresis sessions. Each of these harvest methods incur
average costs over $15,000 per collection.
We have developed a novel harvest device, the “MarrowMiner”
for the rapid, minimally invasive extraction of bone marrow. This
method utilizes a single marrow entry site into the ileac bone,
through which a ﬂexible, powered, guidable catheter is able to
access the majority of the accessible marrow space. The Marrow-
Miner device will enable a single operator to rapidly harvest mar-
row in the outpatient setting, signiﬁcantly facilitating convenient,
on-demand stem cell collection, and should signiﬁcantly reduce
harvest costs and morbidity. Collected marrow could be utilized
immediately, or undergo manipulation for a variety of current and
potential future therapeutic indications.
The MarrowMiner device has been under preclinical develop-
ment in benchtop models, miniature swine and proof of concept
work in human cadavers. Data from device development will be
presented as a clinical grade version is being readied for human use.
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A PILOT TRIAL OF UNRELATED DONOR UMBILICAL CORD BLOOD
TRANSPLANATION (UCBT) AUGMENTED WITH CYTOKINE-PRIMED AL-
DEHYDE DEHYDROGENASE-BRIGHT (ALDHBR) CELLS
Kurtzberg, J.1, Balber, A.2, Mendizabal, A.3, Reese, M.1, Kaestner, A.1,
Gentry, T.2, Hickerson, D.2, Allen, C.3, Sledge, L.S.1, Deibert, E.2,
Allison, J.1, Baker, J.1, Haley, N.R.2 1Duke University Medical Center,
Durham, NC; 2Aldagen Incorporated, Durham, NC; 3The EMMES
Corporation, Rockville, MD.
The major obstacles to UCBT are delayed engraftment and
immune reconstitution due to the lower cell dose. Ex vivo expan-
sion of a portion of the CB graft to increase the number of cells
available for transplantation has been attempted with little to no
affect. We hypothesized that the expanded cells terminally differ-
entiated in culture exhauting their ability to further expand in vivo.
ALDHbr cells in cord blood are enriched for stem and progenitor
cells. These cells were cultured cells ex vivo with expansion of
mature and immature progenitors. We hypothesized that cells
would undergo further expansion if they were primed ex vivo for a
few days and then infused in vivo. We conducted a trial to test the
safety and feasibility of selecting, priming and infusing ALDHbr
cells isolated by high speed ﬂow cytometry from the 20% fraction
of banked CB stored in a dual compartment bags. ALDHbr cells
were isolated 6 days prior to transplant and primed in culture with
cytokines for 5 days. Release criteria included cell count, viability
and negative gram stain. Primed cells were infused 4 hours after
the conventional graft (80% fraction) on day 0. After written
informed consent, patients received sorted but unexpanded cells
(n4) or sorted and primed cells (n10). Safety was the primary
endpoint. Secondary endpoints included engraftment, immune re-
constitution and overall survival. Thus far 14 patients, (55% male,
82% Caucasian, median age 1.16 years) with pediatric malignant
(n6) or non-malignant (n8) diagnoses have been treated. CB
precryopreservation cell dose was 13.8910e7/kg with infused
dose 9.5310e7/kg. Four patients received51037cells/kg from
the 80% fraction. The yield of ALDHbr cells post sort was 50-
110K and remained stable during priming. No patient experienced
infusional toxicity. One patient died of persistant pulmonary hy-
pertension shortly after transplant. The other patients all survive
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from 1-11 months post transplant. Favorable engraftment and
survival was seen as compared to a control group from the COBLT
study. The cummulative incidence of neutrophil engraftment by
day 42 (median  17 days) and platelet engraftment by day 100
(median 50 days) were 90.9% (95% CI 78-100) [p0.001) and
79.5% (95% CI 63.6-95.5%) [p0.003]. Overall survival at 180
days was 92.8% (95% CI 63.6-95.5) [p0.001]. CD4 recovery was
accelerated. Isolation and priming of ALDHbr cells is feasible and
safe. Favorable effects on engraftment and survival were observed.
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VALIDATION STUDY OF MONONUCLEAR CELL RECOVERY USING THE
AXP AUTOXPRESS PLATFORM
Li, J.1, Zhu, H.1, Nguyen, M.1, Emmanuel, P.1, Baker, B.1, Marr, D.1,
Weatherford, C.1, Chapman, J.1 1Thermogenesis Co., Rancho Cordova,
CA.
BACKGROUND: The AXP AutoXpress Platform has been
developed for automatically processing cord blood stem cells be-
fore cryopreservation. The platform consists of a microprocessor-
controlled device, docking station, functionally closed sterile dis-
posable bag set and supporting XpressTRAK™ software. Cord
blood is sterilely transferred to the bag set and centrifuged in the
device at high and low speeds. During the high speed spin, the cells
separate into layers according to density and during the low speed
spin the device transfers the red blood cells (RBC) into the RBC
bag, mononuclear cells (MNC) into the freezing bag and retains
the plasma in the processing/plasma bag. The MNC volume in the
freezing bag is operator selected and achieved with an analytical
balance built into the AXP device. After being mixed with 5 ml
cryoprotectant, the 25 ml MNC solution in the freezing bag can be
directly frozen at a controlled rate and stored in the robotic
BioArchive® System.
STUDY DESIGN: The validation study was designed and per-
formed to determine the efﬁciency of MNC recovery with and
without addition of 20% HES before processing. High speed
centrifugation was 1400xg for 20 minutes and low speed spin 80xg
for 10 or 20 min. Human peripheral blood was used in the study to
serve as a surrogate for cord blood. Blood volumes investigated
were 60, 120 and 170 ml. In addition to MNC recovery, other
parameters such as WBC recovery, red cell reduction, hematocrit,
ﬁnal volume in the freezing bag, and cell mass balance in the
freezing, RBC and processing bags were also measured.
RESULTS: Results are presented as the mean  S.D. for MNC
recovery value. The following table summarizes MNC cell recov-
ery from human peripheral blood in the freezing bag with 60, 120
and 170 ml of initial blood volume in the presence or absence of
20% HES.
CONCLUSION: The AXP AutoXpress Platform consistently
yields MNC recovery greater than 90% with processing blood
volume at 60 and 120 ml without HES addition. Adding 20% HES
remarkably enhances average MNC recovery to greater than 90%
when blood volume processed is 170 ml. The results from this
study demonstrate that the AXP AutoXpress Platform can achieve
automated volume reduction of blood with high efﬁciency of
MNC recovery.
N
Low
speed
centrifuge
Volumes
(mL)
MNC
recovery
(%)
HES
addition
12 80xg, 20min 60 91.5  4.8 20% HES
12 80xg, 20min 170 92.3  5.4 20% HES
8 80xg, 10min 60 96.0  6.0 20% HES
8 80xg, 10min 170 98.7  5.4 20% HES
8 80xg, 10min 60 98  5 no HES
8 80xg, 10min 120 92  14 no HES
8 80xg, 10min 170 78  15 no HES
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A COMPARISON OF THE TRADITIONAL WATER-BATH VS. DRY THAW-
ING METHOD FOR THAWING CRYOPRESERVED PERIPHERAL STEM
CELL COMPONENTS WITH A GOAL OF REDUCING THE CONTAMINA-
TION RISKS
Merkel, D.1, Trieu, K.1 1University of Kansas Hospital, Kansas City,
KS.
The thawing of cryopreserved products has traditionally been
done using a water-bath. The potential contamination risks in-
volved with thawing cryopreserved stem cell products are always a
concern. A safer, more standardized method of thawing cryopre-
served products while reducing the contamination risk associated
with water-baths was investigated. A comparison study was per-
formed using the Equitherm Model 299-733 water-bath and the
Cytotherm® Model D1 Dry Plasma Thawing unit. Two equivalent
cryopreserved bags from each of nine peripheral stem cell collec-
tions were thawed using both water-bath and dry thawing meth-
ods. Bag volumes, storage, cell concentrations, initial product tem-
perature and initial equipment temperature were identical.
Measured parameters included post-thaw cell viability, product
temperature, Lactate Dehydrogenase (LDH) levels and tempera-
ture recovery time of the equipment. All products were placed into
an over-wrap bag. Viabilities found using each method were un-
remarkable with a variation range of less than 5% and an average
variation of less than 1%. The differences noted were: 1) the
products thawed in the water-bath had a temperature range of
–2.0°C to 24.4°C post-thaw versus a temperature range of 6.0°C to
13.6°C following dry thawing method, 2) LDH levels of products
thawed in the water-bath had LDH levels averaging 37.5% higher
with a range of 5.8% to 87.8% higher than dry thawing method, 3)
temperature recovery of the water-bath to desired temperature
averaged 8.9 minutes compared to 4 minutes using the dry thawing
unit. After performing this comparison, it was observed that the
dry thawing method may have beneﬁts over the traditional water-
bath method. The beneﬁts of the dry thawing method include: 1)
the reduced risk of product contamination, 2) lower LDH levels on
the thawed products which may indicate less cell destruction or
lysis, 3) a consistent post-thaw temperature of the product ensuring
that the product is not over-warmed or under-thawed, 4) faster
temperature recovery of the equipment following each thaw allow-
ing for a consistent starting temperature when performing multiple
thaws, 5) elimination of the need to hand manipulate the product
during the thawing process, 6) lastly, the dry thawing unit was very
portable with no water to maintain.
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RIGOROUS PROTOCOLS USING ALEMTUZUMAB TO T CELL DEPLETE
STEM CELL PRODUCTS
Talmadge, J.E.1, Gulen, D.1, Bociek, R.G.1 1University of Nebraska
Medical Center, Omaha, NE.
The therapeutic effect of allogeneic peripheral stem cell trans-
plantation (alloPSCT) is related to an immune-mediated graft-
versus-tumor (GVT) effect. However, alloPSCT is limited by
T-cell mediated graft-versus-host disease(GVHD). Approaches
used to treat or prevent GVHD include in vitro or in vivo purging
of T cells using monoclonal antibodies such as Alemtuzumab,
which is directed against CD52 on B and T lymphocytes, mono-
cytes, and some dendritic cells (DCs). Alemtuzumab has been
injected systemically to treat established GVHD, and ex vivo to
purge T cells from stem cell products (SCPs) to reduce GVHD
induction. T-cell depletion with Alemtuzumab infusion is an ef-
fective method to treat GVHD but is also associated with relapse
and infectious disease. Ex vivo purging by the addition Alemtu-
zumab to a SCP, shaking for 15 minutes and infusion is also
effective. However, the efﬁcacy of this T cell purging protocol can
not be assessed and potentially results Alemtuzumab infusion. The
present study examined the effect of Alemtuzumab co-incubation
on cellular subsets and the mechanism of purging i.e. antibody
dependant cellular cytotoxicity (ADCC) vs. antibody-complement
toxicity. Our studies revealed that cellular concentration is critical
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